共 157 条
[1]
Abrams P(2002)The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 167-78
[2]
Cardozo L(2014)The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients Age Ageing 43 666-75
[3]
Fall M(2003)Prevalence and burden of overactive bladder in the United States World J Urol 20 327-36
[4]
Griffiths D(2000)Comorbidities associated with overactive bladder Am J Manag Care 6 S574-9
[5]
Rosier P(2001)Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder Am J Manag Care 7 S62-75
[6]
Ulmsten U(2008)Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan J Manag Care Pharm 14 291-301
[7]
Wagg A(2010)Patient-reported reasons for discontinuing overactive bladder medication BJU Int 105 1276-82
[8]
Cardozo L(2009)Japanese Society of Neurogenic Bladder. Clinical guideline for male lower urinary tract symptoms Int J Urol 16 775-90
[9]
Nitti VW(2011)Japanese Urological Association. Outline of JUA clinical guidelines for benign prostatic hyperplasia Int J Urol 18 741-56
[10]
Castro-Diaz D(2014)Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year Int J Urol 21 960-7